Table 4.
Characteristics of the reported adverse events.
| Adverse events | Total (n = 494) | SOF + RBV (n = 162) | SOF/DCV ± RBV (n = 41) | OBV/PTV/r/DSV ± RBV (n = 212) | EBR/GZR (n = 64) | DCV + ASV (n = 15) |
|---|---|---|---|---|---|---|
| Fatigue | 47 (9.5) | 15 (9.3) | 8 (19.5) | 21 (9.9) | 2 (3.1) | 1 (6.7) |
| Headache | 14 (2.8) | 4 (2.5) | 2 (4.9) | 8 (3.8) | 0 (0) | 0 (0) |
| Dizziness | 29 (5.9) | 7 (4.3) | 3 (7.3) | 13 (6.1) | 5 (7.8) | 1 (6.7) |
| Insomnia | 14 (2.8) | 5 (3.1) | 4 (9.8) | 2 (4.7) | 2 (3.1) | 1 (6.7) |
| Diarrhea | 3 (0.6) | 1 (0.6) | 0 (0) | 1 (0.5) | 1 (1.6) | 0 (0) |
| Nausea | 11 (2.2) | 2 (1.2) | 1 (2.4) | 5 (2.4) | 2 (3.1) | 1 (6.7) |
| Vomiting | 11 (2.2) | 0 (0) | 1 (2.4) | 7 (3.3) | 3 (4.7) | 0 (0) |
| Anemia | 37 (7.5) | 21 (12.9) | 5 (12.2) | 11 (5.2) | 0 (0) | 0 (0) |
| Abnormal liver function | 24 (4.9) | 8 (4.9) | 3 (7.3) | 10 (4.7) | 1 (1.6) | 2 (13.3) |
Data expressed as sample size and proportion (%).
SOF, sofosbuvir; RBV, ribavirin; DCV, daclatasvir; EBR/GZR, elbasvir/grazoprevir; OBV/PTV/r/DSV, ombitasvir/paritaprevir/ritonavir and dasabuvir; ASV, asunaprevir.